Exicure price to sales ratio XCUR

Market value divided by revenue over the last twelve months, since 2018.

Today, Oct 23, 2026: n/m; not in our data today
Last meaningful: 74.4×; Jun 2025
8-year median: 10.3×
8-year range: -54.0× to 195×
Peer median: 1.4×

Exicure has no meaningful price to sales ratio today: it is not in our data for Oct 23, 2026.

It was last meaningful in Jun 2025, at 74.4×.

On the days it had one over the last 8 years, its median was 10.3×, from -54.0× in Apr 2022 to 195× in Feb 2020.

Price to sales ratio over time

Open the interactive chart, with overlays and comparisons

Year by year

Year	End of year	Low	High
2025	74.4×	37.1×	178×
2024	76.4×	0.1×	128×
2023	0.2×	0.2×	0.8×
2022	0.6×	-54.0×	16.4×
2021	-7.2×	-17.7×	34.0×
2020	9.2×	7.5×	195×
2019	193×	56.3×	193×
2018	72.4×	30.7×	84.4×

Against its peers

Companies in Healthcare nearest Exicure's size, closest first, today.

Company	Price to sales ratio
XCURExicure	n/m
NEPHNephros	1.9×
ATNMActinium Pharmaceuticals	n/m
APTAlpha Pro Tech	0.9×
SPROSpero Therapeutics	1.4×
Peer median	1.4×

What the price to sales ratio tells you

Market value divided by revenue over the last twelve months. Useful for companies with little or no profit yet, since sales are harder to make negative than earnings.

Ignores margins entirely. A software company at 10× sales with 30% margins can be cheaper than a grocer at 1× sales with 2% margins.

More on Exicure

Valuation data, not investment advice. Prices as of Oct 23, 2026. Reported figures come from the company's filings with the SEC.